In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Akebia Therapeutics, Inc.

https://akebia.com/

Latest From Akebia Therapeutics, Inc.

Deal Watch: Adaptimmune, TCR2 Join Forces As Cell Therapy Company Focused On Solid Tumors

All-stock merger will create new company owned 75% by Adaptimmune’s shareholders. Grifols, Selagine to explore antibody approach to treating dry eye disease, and other recent deals.

Deal Watch Business Strategies

After US Woes, Akebia Celebrates EU Nod For Vafseo

The US biotech is in the throes of an appeal to the FDA against the rejection of its HIF-PH inhibitor but regulators in the EU have looked more kindly on vadadustat, which will be sold as Vafseo.

Approvals Renal

EMA Backs Approval For Eight New Drugs But Rejects Lagevrio For COVID-19

Janssen’s Akeega is among the latest drugs that the European Medicines Agency says should be approved for use in the EU. Meanwhile, MSD/Ridgeback Biotherapeutics plan to appeal the agency’s rejection of their COVID-19 treatment.

Approvals Europe

EU Decision Time For Zejula/Zytiga Combo Therapy, Vadadustat & Other Drugs

The European Medicines Agency’s human medicines committee, the CHMP, is this week deciding whether to back the approval of a number of new drugs.

Europe Approvals
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Access Oncology
    • AOI Pharma, Inc.
    • Keryx Biopharmaceuticals Inc.
UsernamePublicRestriction

Register